Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449293 | 0.91 | MEN1 (0.45) | MEN1KMT2AFABP4EDNRALMNA | |
| SCHEMBL4448425 | 0.89 | TP53 (0.46) | MEN1KMT2APOLBHTTEDNRA | |
| SCHEMBL4445805 | 0.87 | TP53 (0.47) | MEN1KMT2AFABP4HTTEDNRA | |
| SCHEMBL4448161 | 0.85 | NPY5R (0.50) | MEN1KMT2APOLBEDNRA | |
| SCHEMBL4449069 | 0.85 | EDNRA (0.51) | MEN1KMT2ANAMPTPOLBEDNRA | |
| SCHEMBL4447174 | 0.84 | KDM4E (0.51) | KMT2ANAMPTKDM4EEDNRALMNA | |
| SCHEMBL4622884 | 0.84 | NSD2 (0.52) | KMT2AEDNRA | |
| SCHEMBL4448268 | 0.84 | MCL1 (0.55) | MEN1KMT2AKDM4EPOLBEDNRA | |
| SCHEMBL4448820 | 0.83 | EDNRA (0.49) | KMT2AEDNRA | |
| SCHEMBL4444610 | 0.83 | FABP4 (0.51) | FABP4EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547716-B2 | Sulfonamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-06-16 | — | — | US | disclosed |
| EP-1402890-B1 | SULFONAMIDE DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-20040234622-A1 | Sulfonamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1402890-A1 | SULFONAMIDE DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234622-A1 | Sulfonamide derivatives | PCNA, TOP2A, DDB1 | MEN1 4723/4885KMT2A 460/4885FABP4 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.